Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with ...
A rare clotting disorder puzzled doctors during the COVID vaccine rollout. New research reveals the unlikely chain of events ...
AstraZeneca has kept pace with drug rival Pfizer in striking a pricing deal with the Trump White House. AstraZeneca PLC announced a deal with President Donald Trump that's focused on lowering drug ...
LONDON/NEW YORK (Reuters) - The co-leaders of research at Pfizer Inc split up on Wednesday as Martin Mackay left to head research at rival drugmaker AstraZeneca Plc , leaving Mikael Dolsten in charge.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results